(Q35223873)

7 August 2017

title

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line (English)

1 reference

7 August 2017

0 references

1 reference

11

Fumihiro Tanaka

1 reference

7 August 2017

Shigeki Nanjo

1

1 reference

7 August 2017

Takayuki Nakagawa

2

1 reference

7 August 2017

Shinji Takeuchi

3

1 reference

7 August 2017

Kenji Kita

4

1 reference

7 August 2017

Koji Fukuda

5

1 reference

7 August 2017

Mitsutoshi Nakada

6

1 reference

7 August 2017

Hisanori Uehara

7

1 reference

7 August 2017

Hiroshi Nishihara

8

1 reference

7 August 2017

Eiji Hara

9

1 reference

7 August 2017

Hidetaka Uramoto

10

1 reference

7 August 2017

Seiji Yano

12

1 reference

7 August 2017

publication date

17 February 2015

1 reference

7 August 2017

1 reference

7 August 2017

volume

106

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

244-252

1 reference

describes a project that uses

7 August 2017

A925L

0 references

A925LPE3

0 references

cites work

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Ceritinib in ALK-rearranged non-small-cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

ALKoma: a cancer subtype with a shared target

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Treating ALK-positive lung cancer--early successes and future challenges

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

A mouse model for EML4-ALK-positive lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4376432

Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy.

27 July 2018

1 reference

Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.

21 January 2018

1 reference

NKX2.2 suppresses self-renewal of glioma-initiating cells.

21 January 2018

1 reference

A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer

21 January 2018

1 reference

Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

Novel metastasis model of human lung cancer in SCID mice depleted of NK cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25581823

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/CAS.12600

1 reference

release_vx6immhgp5hi7czdruwqkldstu

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vx6immhgp5hi7czdruwqkldstu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

4376432

1 reference

7 August 2017

1 reference